Mustang Bio (MBIO) Research & Development (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Research & Development of $178000.0 for Q1 2026, up 118.46% year-over-year from $81477.7 in Q1 2025, and up 156.15% quarter-over-quarter from -$317000.0 in Q4 2025.
Mustang Bio (MBIO) Research & Development (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Research & Development for 11 consecutive years, with $178000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 118.46% year-over-year to $178000.0; the TTM figure through Mar 2026 stood at -$374000.0 (down 110.25% YoY), while the FY2025 annual figure was -$1.5 million, down 118.01% from the prior year.
- Research & Development rose to $178000.0 in Q1 2026 per MBIO's latest filing, from -$317000.0 in the prior quarter.
- Across five years, Research & Development topped out at $16.3 million in Q1 2022 and bottomed at -$964000.0 in Q1 2025.
- Historically, Research & Development has averaged $6.5 million across 5 years, with a median of $4.4 million in 2024.
- Annual changes were most pronounced in 2025 — Research & Development slumped 684.21% — and 2026, when it jumped 118.46%.
- Mustang Bio's Research & Development stood at $15.6 million in 2022, then tumbled by 60.58% to $6.1 million in 2023, then sank by 96.8% to $197000.0 in 2024, then slumped by 260.91% to -$317000.0 in 2025, then surged by 156.15% to $178000.0 in 2026.
- Business Quant data shows MBIO's Research & Development at $178000.0 in Q1 2026, -$317000.0 in Q4 2025, and -$333000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Mustang Bio | 3.82 Mn | 3.82 Mn | - | 224,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 224,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | -317,000.00 |
| Sep 30, 2025 | -333,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Mar 31, 2025 | -964,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 6.15 Mn |
| Sep 30, 2023 | 9.53 Mn |
| Jun 30, 2023 | 10.84 Mn |
| Mar 31, 2023 | 14.00 Mn |
| Dec 31, 2022 | 15.60 Mn |
| Sep 30, 2022 | 15.42 Mn |
| Jun 30, 2022 | 15.16 Mn |
| Mar 31, 2022 | 16.29 Mn |
| Dec 31, 2021 | 13.26 Mn |
| Sep 30, 2021 | 14.08 Mn |